Invikafusp Alfa Earns FDA Fast Track Designation in Locally Advanced CRC
Phase 1 data support the fast track designation for invikafusp alfa in advanced colorectal cancer with high tumor mutational burden.
Related Articles
New Horizons in HSCT-TMA: Expert Perspectives and Pearls for Practice
This live educational event is intended for learners to be better able to understand the dynamic data evaluating diagnostic and care strategies for hematopoi…
FDA Approves Axatilimab in 9 Mg and 22 Mg Vial Sizes for GVHD
The developers expect the product to be available for order in the United States in early February 2025.
FDA Clears Investigational New Drug Application for R-5780 in Solid Tumors
The RISE R-5780-01 trial will evaluate the safety and tolerability of R-5780 in patients with melanoma, basal cell carcinoma, or squamous cell carcinoma.
Sotorasib Plus Panitumumab Approved for Patients With KRAS G12C-Mutated Colorectal Cancer
Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal…
Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial
PURPOSETo evaluate the cost utility of a 9-month supervised exercise program for patients with metastatic breast cancer (mBC), compared with control (usual care, supplemented with…
Cancer statistics, 2025
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data…
Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the…
SABCS 2024: Key Takeaways From Data on Elacestrant
Hope S. Rugo, MD, FASCO, discusses key takeaways from SABCS 2024 conference.
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
PURPOSEOver the past 15 years, the landscape of early phase clinical trials (EPCTs) has undergone a remarkable expansion in both quantity and intricacy. The proliferation…
Genetic testing for Lynch Syndrome prevents cancers being missed
Genetic testing for Lynch Syndrome must increase to prevents cancers being missed
